Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study

References

• CRN. Cancer in Norway 2016 - Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway; 2017 Available from: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2016/cin-2106.pdf.
   Google Scholar
• Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134–140. doi:10.1111/bjd.1551028369739
   PubMed Web of Science ®Google Scholar
• Arnold M, de Vries E, Whiteman DC, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer. 2018. doi:10.1002/ijc.31527
   Web of Science ®Google Scholar
• Berwick M, Buller DB, Cust A, et al. Melanoma epidemiology and prevention In: Kaufman HL, Mehnert JM, editors. Melanoma. Cham: Springer International Publishing; 2016:17–49.
   Google Scholar
• Robsahm TE, Karagas MR, Rees JR, Syse A. New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway. BMC Cancer. 2014;14(1):210. doi:10.1186/1471-2407-14-21024645632
   PubMed Web of Science ®Google Scholar
• Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Clin Investig Dermatol. 2003;120(2):217–223. doi:10.1046/j.1523-1747.2003.12041.x
   Google Scholar
• Stenehjem JS, Veierod MB, Nilsen LT, et al. Anthropometric factors and cutaneous melanoma: prospective data from the population-based Janus Cohort. Int J Cancer. 2018;142(4):681–690. doi:10.1002/ijc.v142.428983909
   PubMed Web of Science ®Google Scholar
• De Giorgi V, Gori A, Savarese I, et al. Role of BMI and hormone therapy in melanoma risk: a case–control study. J Cancer Res Clin Oncol. 2017;143(7):1191–1197. doi:10.1007/s00432-017-2387-528289899
   PubMed Web of Science ®Google Scholar
• Rota M, Pasquali E, Bellocco R, et al. Alcohol drinking and cutaneous melanoma risk: a systematic review and dose–risk meta-analysis. Br J Dermatol. 2014;170(5):1021–1028. doi:10.1111/bjd.2014.170.issue-524495200
   PubMed Web of Science ®Google Scholar
• de Vries E, Trakatelli M, Kalabalikis D, et al. Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study. Br J Dermatol. 2012;167(Suppl 2):1–13. doi:10.1111/bjd.2012.167.issue-s2
   PubMed Web of Science ®Google Scholar
• Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20(3):127–150.22271002
   PubMedGoogle Scholar
• Le CP, Nowell CJ, Kim-Fuchs C, et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nat Commun. 2016;7:10634. doi:10.1038/ncomms1063426925549
   PubMed Web of Science ®Google Scholar
• Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract. 2011;61(590):e565–e572. doi:10.3399/bjgp11X59384822152736
   PubMed Web of Science ®Google Scholar
• Gomez-Lumbreras A, Ferrer P, Ballarin E, et al. Study of antidepressant use in 5 European settings. Could economic, sociodemographic and cultural determinants be related to their use? J Affect Disord. 2019;249:278–285. doi:10.1016/j.jad.2019.01.03930784725
   PubMed Web of Science ®Google Scholar
• NorPD. Statistics from the Norwegian Prescription Database. Norwegian Institute of Public Health; 2019 Available from: http://www.norpd.no/Prevalens.aspx. Accessed 87, 2019.
   Google Scholar
• Hartz I, Skurtveit S, Hjellvik V, Furu K, Nesvag R, Handal M. Antidepressant drug use among adolescents during 2004–2013: a population-based register linkage study. Acta Psychiatr Scand. 2016;134(5):420–429. doi:10.1111/acps.2016.134.issue-527571234
   PubMed Web of Science ®Google Scholar
• Daley E, Wilkie D, Loesch A, et al. Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun. 2005;328(2):623–632. doi:10.1016/j.bbrc.2005.01.02815694394
   PubMed Web of Science ®Google Scholar
• Frick LR, Rapanelli M. Antidepressants: influence on cancer and immunity? Life Sci. 2013;92(10):525–532. doi:10.1016/j.lfs.2013.01.02023369745
   PubMed Web of Science ®Google Scholar
• Sternbach H. Are antidepressants carcinogenic? A review of preclinical and clinical studies. J Clin Psychiatry. 2003;64(10):1153–1162. doi:10.4088/JCP.v64n100314658962
   PubMed Web of Science ®Google Scholar
• Grygier B, Arteta B, Kubera M, et al. Inhibitory effect of antidepressants on B16F10 melanoma tumor growth. Pharmacol Rep. 2013;65(3):672–681. doi:10.1016/S1734-1140(13)71045-423950590
   PubMed Web of Science ®Google Scholar
• Parker KA, Glaysher S, Hurren J, et al. The effect of tricyclic antidepressants on cutaneous melanoma cell lines and primary cell cultures. Anticancer Drugs. 2012;23(1):65–69. doi:10.1097/CAD.0b013e32834b189421897201
   PubMed Web of Science ®Google Scholar
• Reddy KK, Lefkove B, Chen LB, et al. The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment Cell Melanoma Res. 2008;21(4):451–456. doi:10.1111/j.1755-148X.2008.00481.x18710373
   PubMed Web of Science ®Google Scholar
• Gandini S, Palli D, Spadola G, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1–9. doi:10.1016/j.critrevonc.2017.12.00329458778
   PubMed Web of Science ®Google Scholar
• Tang H, Fu S, Zhai S, Song Y, Han J. Use of antihypertensive drugs and risk of malignant melanoma: a meta-analysis of observational studies. Drug Saf. 2017;41:161–169.
   Web of Science ®Google Scholar
• Berge LAM, Andreassen BK, Stenehjem JS, et al. Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case–control study. BMJ Open. 2019;9(2):e025246. doi:10.1136/bmjopen-2018-025246
   Web of Science ®Google Scholar
• Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86–94. doi:10.1111/j.1742-7843.2009.00494.x19961477
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for ATC Classification and DDD Assignment 2015. Norwegian Institute of Public Health; 2016.
   Google Scholar
• Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Sørensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case–control study. Br J Cancer. 2008;99(9):1522–1528. doi:10.1038/sj.bjc.660468618813314
   PubMed Web of Science ®Google Scholar
• Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: photoallergic and phototoxic reactions. Clin Dermatol. 2016;34(5):571–581. doi:10.1016/j.clindermatol.2016.05.00627638435
   PubMed Web of Science ®Google Scholar
• Pottegard A, Friis S, Sturmer T, Hallas J, Bahmanyar S. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol. 2017;122:451–459.
   Web of Science ®Google Scholar
• Selvag E. [Drugs and sun]. Tidsskr nor Laegeforen. 2003;123(13–14):1860–1861.12830267
   PubMedGoogle Scholar
• Medhaug I, Olseth JA, Reuder J. UV radiation and skin cancer in Norway. J Photochem Photobiol B. 2009;96(3):232–241. doi:10.1016/j.jphotobiol.2009.06.01119628404
   PubMed Web of Science ®Google Scholar
• Robsahm TE, Tretli S. Cutaneous malignant melanoma in Norway: variation by region of residence before and after the age 17. Cancer Causes Control. 2001;12(6):569–576. doi:10.1023/A:101128791840511519765
   PubMed Web of Science ®Google Scholar
• Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47(17):2607–2617. doi:10.1016/j.ejca.2011.04.02321620689
   PubMed Web of Science ®Google Scholar
• Karagas MR, Zens MS, Stukel TA, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control. 2006;17(1):11–19. doi:10.1007/s10552-005-0281-y16411048
   PubMed Web of Science ®Google Scholar
• Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol. 1993;22(6):1189–1192. doi:10.1093/ije/22.6.11898144304
   PubMed Web of Science ®Google Scholar
• R Core Team (2019).R: A Language and Environment for Statistical Computing.R Foundation for Statistical Computing, Vienna, Austria Available from: https://www.R-project.org/.
   Google Scholar
• Jia Y, Li F, Liu YF, Zhao JP, Leng MM, Chen L. Depression and cancer risk: a systematic review and meta-analysis. Public Health. 2017;149:138–148. doi:10.1016/j.puhe.2017.04.02628641155
   PubMed Web of Science ®Google Scholar
• Dikmen M, Cantürk Z, Öztürk Y. Escitalopram oxalate, a selective serotonin reuptake inhibitor, exhibits cytotoxic and apoptotic effects in glioma C6 cells. Acta Neuropsychiatr. 2011;23(4):173–178. doi:10.1111/j.1601-5215.2011.00550.x25379795
   PubMed Web of Science ®Google Scholar
• Yuan S-Y, Cheng C-L, Ho H-C, et al. Nortriptyline induces mitochondria and death receptor-mediated apoptosis in bladder cancer cells and inhibits bladder tumor growth in vivo. Eur J Pharmacol. 2015;761:309–320. doi:10.1016/j.ejphar.2015.06.00726086857
   PubMed Web of Science ®Google Scholar
• Kirkova M, Tzvetanova E, Vircheva S, Zamfirova R, Grygier B, Kubera M. Antioxidant activity of fluoxetine: studies in mice melanoma model. Cell Biochem Funct. 2010;28(6):497–502. doi:10.1002/cbf.168220803706
   PubMed Web of Science ®Google Scholar
• Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, Huybrechts KF. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers’ financial associations with industry. PLoS One. 2011;6(4):e18210. doi:10.1371/journal.pone.001821021494667
   PubMed Web of Science ®Google Scholar
• Reeves KW, Okereke OI, Qian J, Tamimi RM, Eliassen AH, Hankinson SE. Depression, antidepressant use, and breast cancer risk in pre- and postmenopausal women: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2018;27(3):306–314. doi:10.1158/1055-9965.EPI-17-070729263188
   PubMed Web of Science ®Google Scholar
• Mørch LS, Dehlendorff C, Baandrup L, Friis S, Kjaer SK. Use of antidepressants and risk of epithelial ovarian cancer. Int J Cancer. 2017;141(11):2197–2203. doi:10.1002/ijc.v141.1128791695
   PubMed Web of Science ®Google Scholar
• Harlow BL, Cramer DW, Baron JA, Titus-Ernstoff L, Greenberg ER. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1998;7(8):697–702.9718222
   PubMed Web of Science ®Google Scholar
• Stoer NC, Botteri E, Ghiasvand R, et al. Reproductive factors and risk of melanoma: a population-based cohort study. Br J Dermatol. 2019;181(2):282–289. doi:10.1111/bjd.2019.181.issue-230748007
   PubMed Web of Science ®Google Scholar
• Botteri E, Stoer NC, Weiderpass E, Pukkala E, Ylikorkala O, Lyytinen H. Menopausal hormone therapy and risk of melanoma: a nationwide register-based study in Finland. Cancer Epidemiol Biomarkers Prev. 2019;28:1857–1860. doi:10.1158/1055-9965.EPI-19-055431455672
   PubMed Web of Science ®Google Scholar
• Hodgetts S, Gallagher P, Stow D, Ferrier IN, O’Brien JT. The impact and measurement of social dysfunction in late-life depression: an evaluation of current methods with a focus on wearable technology. Int J Geriatr Psychiatry. 2017;32(3):247–255. doi:10.1002/gps.463227911019
   PubMed Web of Science ®Google Scholar
• Gillen MM, Markey CN. The role of body image and depression in tanning behaviors and attitudes. Behav Med. 2012;38(3):74–82. doi:10.1080/08964289.2012.68549922873732
   PubMed Web of Science ®Google Scholar
• Heckman CJ, Munshi T, Darlow S, et al. The association of tanning behavior with psycho-tropic medication use among young adult women. Psychol Health Med. 2016;21(1):60–66. doi:10.1080/13548506.2015.105106026068581
   PubMed Web of Science ®Google Scholar
• Pottegard A, Christensen R, Houji A, et al. Primary non-adherence in general practice: a Danish register study. Eur J Clin Pharmacol. 2014;70(6):757–763. doi:10.1007/s00228-014-1677-y24756147
   PubMed Web of Science ®Google Scholar
• Hafferty JD, Campbell AI, Navrady LB, et al. Self-reported medication use validated through record linkage to national prescribing data. J Clin Epidemiol. 2018;94:132–142. doi:10.1016/j.jclinepi.2017.10.01329097340
   PubMed Web of Science ®Google Scholar